Clinical Trial Update: Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating carboplatin and eribulin mesylate in triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Male Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Stage Ia Breast Cancer
• Stage Ib Breast Cancer
• Stage Iiia Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ERIBULIN MESYLATE (Eribulin mesylate)

Snippet

Sponsor: Northwestern University | Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: UNKNOWN